Komori
General Meetings of Shareholders4503Astellas Pharma Inc.Pharmaceuticals

Notice Regarding the Partial Withdrawal of Proposals to Be Submitted to the 21st Annual General Meeting of Shareholders

Due to the withdrawal and resignation of 1 outside director nominee, the proposal for the election of directors at the annual general meeting has changed from 7 nominees to 6. The candidate numbers will not be renumbered, and the descriptions concerning the withdrawing nominee will be deleted from the notice of convocation.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
1
Number of director nominees (changed from 7 to 6)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (21st fiscal year)
2026
Jun 19
Date and time20 days from this disclosure to the meeting
Matters for resolution2 items
  1. Election of 6 directors (excluding directors who are Audit & Supervisory Committee Members)

  2. Not disclosed

Director nominee
6Nominees
0New
5Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (21st fiscal year)
Date and time19 June 2026
Matters for resolutionProposal No. 1: Election of 6 directors (excluding directors who are Audit & Supervisory Committee Members), Proposal No. 2: Not disclosed
Director nominee6 nominees, including 0 new nominees and 5 outside directors
Items this document does not state (2)
Shareholder ProposalPercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Andreas Busch, an outside director nominee, expressed his intention to withdraw his candidacy for outside director.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Partial Withdrawal of Proposals to Be Submitted to the 21st Annual General Meeting of Shareholders | Astellas Pharma Inc. (4503) timely disclosure | Komori